Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 314 Thousand USD | -82.28% |
| 2022 | 1.77 Million USD | -40.2% |
| 2021 | 2.96 Million USD | 182.19% |
| 2020 | 1.05 Million USD | -76.46% |
| 2019 | 4.46 Million USD | -46.8% |
| 2018 | 8.38 Million USD | 109.49% |
| 2017 | 4 Million USD | 19.96% |
| 2016 | 3.33 Million USD | 31.48% |
| 2015 | 2.53 Million USD | -41.25% |
| 2014 | 4.32 Million USD | 0.08% |
| 2013 | 4.31 Million USD | -2.03% |
| 2012 | 4.4 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 72 Thousand USD | 0.0% |
| 2024 Q2 | 72 Thousand USD | 0.0% |
| 2023 Q2 | 72 Thousand USD | -26.53% |
| 2023 FY | 314 Thousand USD | -82.28% |
| 2023 Q3 | 72 Thousand USD | 0.0% |
| 2023 Q4 | 72 Thousand USD | 0.0% |
| 2023 Q1 | 98 Thousand USD | -6.67% |
| 2022 Q4 | 105 Thousand USD | -91.21% |
| 2022 Q2 | 256 Thousand USD | 18.52% |
| 2022 Q1 | 216 Thousand USD | 0.93% |
| 2022 FY | 1.77 Million USD | -40.2% |
| 2022 Q3 | 1.19 Million USD | 366.8% |
| 2021 Q2 | 1.09 Million USD | -24.88% |
| 2021 Q4 | 214 Thousand USD | 2.88% |
| 2021 FY | 2.96 Million USD | 182.19% |
| 2021 Q1 | 1.45 Million USD | 2587.04% |
| 2021 Q3 | 208 Thousand USD | -80.92% |
| 2020 Q2 | 168 Thousand USD | -79.71% |
| 2020 Q3 | - USD | -100.0% |
| 2020 FY | 1.05 Million USD | -76.46% |
| 2020 Q4 | 54 Thousand USD | 0.0% |
| 2020 Q1 | 828 Thousand USD | -5.91% |
| 2019 Q3 | 695 Thousand USD | -72.35% |
| 2019 Q1 | 372 Thousand USD | -21.85% |
| 2019 FY | 4.46 Million USD | -46.8% |
| 2019 Q4 | 880 Thousand USD | 26.62% |
| 2019 Q2 | 2.51 Million USD | 575.81% |
| 2018 FY | 8.38 Million USD | 109.49% |
| 2018 Q4 | 476 Thousand USD | -49.58% |
| 2018 Q3 | 944 Thousand USD | -56.74% |
| 2018 Q2 | 2.18 Million USD | -54.39% |
| 2018 Q1 | 4.78 Million USD | 301.34% |
| 2017 Q1 | 462 Thousand USD | -38.89% |
| 2017 Q2 | 718 Thousand USD | 55.41% |
| 2017 Q3 | 1.63 Million USD | 127.16% |
| 2017 Q4 | 1.19 Million USD | -26.92% |
| 2017 FY | 4 Million USD | 19.96% |
| 2016 FY | 3.33 Million USD | 31.48% |
| 2016 Q1 | 818 Thousand USD | 24.13% |
| 2016 Q2 | 874 Thousand USD | 6.85% |
| 2016 Q3 | 889 Thousand USD | 1.72% |
| 2016 Q4 | 756 Thousand USD | -14.96% |
| 2015 FY | 2.53 Million USD | -41.25% |
| 2015 Q4 | 659 Thousand USD | 31.54% |
| 2015 Q2 | 734 Thousand USD | 13.8% |
| 2015 Q1 | 645 Thousand USD | -1.45% |
| 2015 Q3 | 501 Thousand USD | -31.74% |
| 2014 Q4 | 654.51 Thousand USD | -49.69% |
| 2014 FY | 4.32 Million USD | 0.08% |
| 2014 Q1 | 1.09 Million USD | 0.03% |
| 2014 Q2 | 1.27 Million USD | 16.74% |
| 2014 Q3 | 1.3 Million USD | 2.15% |
| 2013 Q1 | 1.13 Million USD | 0.0% |
| 2013 FY | 4.31 Million USD | -2.03% |
| 2013 Q4 | 1.09 Million USD | 10.88% |
| 2013 Q3 | 983.58 Thousand USD | -10.82% |
| 2013 Q2 | 1.1 Million USD | -3.2% |
| 2012 FY | 4.4 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 99.808% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 99.87% |
| Codexis, Inc. | 70.14 Million USD | 99.552% |
| Organovo Holdings, Inc. | 109 Thousand USD | -188.073% |